Narrative review covers adoptive cell therapy modalities for ovarian cancer.

This narrative review focuses on the landscape of adoptive cell therapy (ACT) modalities for ovarian cancer. The scope encompasses a broad range of cellular approaches, specifically tumor-infiltrating lymphocytes (TILs), chimeric antigen receptor T cells (CAR-T), natural killer (NK) cells, TCR-T, cytokine-induced killer (CIK) cells, and γδ T cells. The authors do not report a specific population, sample size, or setting for these therapies.

The synthesis addresses multiple dimensions of ACT development and application. Key topics include the mechanistic underpinnings of ACT, the immunosuppressive features of the ovarian tumor microenvironment, combinatorial regimens, genetic engineering, cell design, antigen specificity, tumor immune evasion, stromal barriers, clinical trial progress, efficacy outcomes, and translational barriers. The review aims to provide a comprehensive overview of these complex biological and clinical challenges.

Limitations of this narrative approach are inherent in the absence of pooled effect sizes or specific adverse event rates, as these details were not reported in the source material. The authors acknowledge that without specific trial-level data or a defined study phase, the practice relevance remains qualitative. Consequently, clinicians should interpret these findings as a broad conceptual framework rather than definitive guidance for immediate clinical implementation, noting that the evidence is observational and descriptive in nature.